Zembrin® Sceletium Extract

Zembrin® and the scientific and clinical research on Zembrin® applies only to this proprietary standardised Sceletium extract, and not to other Sceletium-based products.

 

Zembrin® is manufactured in a European Union Good Manufacturing Practice (EU-GMP) certified manufacturing facility, and is the first standardised extract ever to have been made from Sceletium.

 

Commercialised with the authorisation of the Department of Environmental Affairs and  the San Council of South Africa, Zembrin® is a plant extract derived from a fully traceable and carefully standardised cultivation of an elite selection of Sceletium tortuosum.

 

elev8_logo

 

Introducing Zembrin®:

Zembrin® is the world’s leading researched and clinically studied extract of Sceletium tortuosum developed over more than a decade by an international team of scientists and physicians

The unique signature of Zembrin® is “alert serenity”.

 

Zembrin® is HG&H Pharmaceuticals’ proprietary standardised extract of cultivated Sceletium tortuosum produced from seeds of their own chemotype.

 

Zembrin® is an evidence-based botanical supplement that has been thoroughly studied for safety and efficacy in comprehensive pre-clinical studies as well as clinical studies.

 

Zembrin® is manufactured to the highest international standards at an EU-GMP certified facility.

 

When HG&H set out to develop Zembrin®, they were determined to formally acknowledge and reward the contribution of the San people who had originally discovered and used the South African plant Sceletium. They have achieved this through a formal benefit sharing agreement with the South African San Council: Africa’s first prior informed consent benefit sharing agreement.

 

Sceletium tortuosum is a protected species and wild harvesting is not sustainable for commercial products. HG&H committed itself at the outset to only use cultivated plant material in the production of Zembrin® to avoid depleting threatened wild plant stocks, and to ensure consistent product quality. They have achieved this by investing in a highly successful new crop development programme, and cultivating their own selection of Sceletium on a large commercial scale.

 

Zembrin® – Fast Facts:

Zembrin® has self-affirmed Generally Recognised As Safe (GRAS) status in the USA.

Zembrin® has been clinically studied for efficacy, with significant positive results. (Paper to be submitted for publication).

Zembrin® has been clinically studied for safety – the first clinical safety study on Sceletium was published in 2013 in the Journal of Alternative and Complementary Medicine.

Zembrin® is patented, with granted patents and new patent applications submitted.

Zembrin® is the only Sceletium extract with published pharmacology.

Zembrin® is manufactured in a certified EU-GMP manufacturing facility, the first standardised extract to have been made from Sceletium.

Zembrin® is produced from HG&H’s own elite naturally occurring chemotype of Sceletium, the first large-scale commercial cultivation of a Sceletium chemotype.

Zembrin® is the only Sceletium product to carry the logo of its indigenous beneficiaries – the South African San Council.

Zembrin® is the only Sceletium product for which an MRI study was done to prove its positive effects on the brain’s responses to anxiety–provoking images.

 
All clinical and preclinical research on Zembrin® applies only to this proprietary standardised Sceletium extract, and not to other Sceletium-based products.